Biotech stocks began the year with gusto, but sold off when the broader-market rally fizzled in February, as investors sought safer havens. Yet, with...
Stocks edged higher this morning amid easing concerns about the debt ceiling as negotiations in Washington gained steam. According to Oppenheimer’s John Stoltzfus, investors...
Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that...